Stock Track | Ironwood Pharmaceuticals Soars 44.47% Intraday on Strong 2026 Revenue Forecast

Stock Track01-02

Ironwood Pharmaceuticals (IRWD) surged 44.47% during the intraday session on Friday, marking one of its most significant single-day gains. The stock's sharp rise followed a broader improvement in market sentiment, but the primary driver was company-specific news.

The biopharmaceutical firm announced a bullish 2026 revenue forecast, projecting $450–$475 million, well above analyst estimates of $319.4 million. Additionally, Ironwood expects adjusted EBITDA to exceed $300 million, fueled by strong demand for its constipation drug, Linzess, which is forecasted to generate $1.125–$1.175 billion in U.S. net sales. The company also maintained its 2025 guidance, reinforcing investor confidence.

CEO Tom McCourt highlighted progress in FDA discussions for a short bowel syndrome treatment, further bolstering optimism. The upbeat outlook reversed the stock's 23.9% decline over the past year, attracting heavy buying interest.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1169306610?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-02 22:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169306610","market":"us","top_or_hot":-1,"title":"Stock Track | Ironwood Pharmaceuticals Soars 44.47% Intraday on Strong 2026 Revenue Forecast","media":"Stock Track","content":"<p>Ironwood Pharmaceuticals (IRWD) surged 44.47% during the intraday session on Friday, marking one of its most significant single-day gains. The stock's sharp rise followed a broader improvement in market sentiment, but the primary driver was company-specific news.</p><p>The biopharmaceutical firm announced a bullish 2026 revenue forecast, projecting $450–$475 million, well above analyst estimates of $319.4 million. Additionally, Ironwood expects adjusted EBITDA to exceed $300 million, fueled by strong demand for its constipation drug, Linzess, which is forecasted to generate $1.125–$1.175 billion in U.S. net sales. The company also maintained its 2025 guidance, reinforcing investor confidence.</p><p>CEO Tom McCourt highlighted progress in FDA discussions for a short bowel syndrome treatment, further bolstering optimism. The upbeat outlook reversed the stock's 23.9% decline over the past year, attracting heavy buying interest.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ironwood Pharmaceuticals Soars 44.47% Intraday on Strong 2026 Revenue Forecast</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ironwood Pharmaceuticals Soars 44.47% Intraday on Strong 2026 Revenue Forecast\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-01-02 22:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ironwood Pharmaceuticals (IRWD) surged 44.47% during the intraday session on Friday, marking one of its most significant single-day gains. The stock's sharp rise followed a broader improvement in market sentiment, but the primary driver was company-specific news.</p><p>The biopharmaceutical firm announced a bullish 2026 revenue forecast, projecting $450–$475 million, well above analyst estimates of $319.4 million. Additionally, Ironwood expects adjusted EBITDA to exceed $300 million, fueled by strong demand for its constipation drug, Linzess, which is forecasted to generate $1.125–$1.175 billion in U.S. net sales. The company also maintained its 2025 guidance, reinforcing investor confidence.</p><p>CEO Tom McCourt highlighted progress in FDA discussions for a short bowel syndrome treatment, further bolstering optimism. The upbeat outlook reversed the stock's 23.9% decline over the past year, attracting heavy buying interest.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IRWD","symbol_name":"Ironwood医药","start_time":0,"source_url":"","article_id":"1169306610","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169306610","pubTimestamp":1767364463,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Ironwood Pharmaceuticals (IRWD) surged 44.47% during the intraday session on Friday, marking one of its most significant single-day gains. The stock's sharp rise followed a broader improvement in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IRWD":"Ironwood医药"},"translate_title":"个股赛道|铁木制药盘中大涨44.47%2026年营收预期强劲","themeId":"b2d4671d65e4a3e3ea3a89bd362ecb9d","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRWD":1},"content_text":"Ironwood Pharmaceuticals (IRWD) surged 44.47% during the intraday session on Friday, marking one of its most significant single-day gains. The stock's sharp rise followed a broader improvement in market sentiment, but the primary driver was company-specific news.The biopharmaceutical firm announced a bullish 2026 revenue forecast, projecting $450–$475 million, well above analyst estimates of $319.4 million. Additionally, Ironwood expects adjusted EBITDA to exceed $300 million, fueled by strong demand for its constipation drug, Linzess, which is forecasted to generate $1.125–$1.175 billion in U.S. net sales. The company also maintained its 2025 guidance, reinforcing investor confidence.CEO Tom McCourt highlighted progress in FDA discussions for a short bowel syndrome treatment, further bolstering optimism. The upbeat outlook reversed the stock's 23.9% decline over the past year, attracting heavy buying interest.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1169306610","isCrawlerRequest":true}